17,261 trials
Early Lumbar Disc Degeneration
Primary: Neurological Assessment for Motor Function and Reflexes/Sensory — 0; 2 participants
Degenerative Disc Disease
Primary: Neurological Assessment for Motor Function and Reflexes/Sensory — 0; 0 participants
Early Lumbar Disc Degeneration
Primary: Neurological Assessment for Motor Function and Reflexes/Sensory — 0; 0 participants
Seasonal Influenza
Primary: Percentage of Participants Who Achieved Seroconversion or Significant Increase in Single Radial Hemolysis (SRH) Area Against Each of Three Vaccine Strains After One…
Multiple Myeloma
Primary: Phase 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability — 3; 3; 6; 3 participants
Common Cold
Primary: Sum of All Symptoms in Viruspositive Persons — 52; 52; 54; 56 units on a scale — p=<0.037
Multiple Myeloma
Primary: Median Investigator-Assessed Progression-free Survival (PFS) Time (Months) From Randomization to Date of First Tumor Progression or Death Due to Any Cause - Randomized…
Allergic Asthma
Primary: FEV1, Late Asthmatic Response (LAR) - Pre-treatment — 0.814; 1.01 ratio
Breast Cancer
Primary: Percentage of Participants Achieving Pathological Complete Response (pCR) — 29.0; 45.8; 16.8; 24.0 percentage of participants — p=0.0094
Migraine
Primary: Migraine Frequency: Change From Baseline 12-week Period to Weeks 1 to 12 — -8.0; 1.0 days
Metastatic Colorectal Cancer
Primary: Objective Response Rate — 56.47; 37.93 percentage of participants
Carcinoma, Non-Small-Cell Lung
Primary: The Primary Goal of This Study is to Show That the Addition of Bevacizumab to Cisplatin-based Chemotherapy in the Neoadjuvant Setting for Non-squamous Cell Carcinomas…
Thymoma · Thymic Carcinoma
Primary: Objective Response Rate (Complete and Partial Response) — 26.7; 9.1 percentage of participants
Non-Hodgkin's Lymphoma
Primary: Complete Remission — 10 participants
Urticaria
Primary: Number of Participants With Adverse Events — 3 participants